Analyses were performed in 2 pooled datasets : Population 1 ( N = 2313 ; mean exposure [ weeks ] : canagliflozin , 24.3 ; placebo , 23.8 ) including patients from 4 placebo-controlled studies ; Population 2 ( N = 9439 ; mean exposure [ weeks ] : canagliflozin , 68.1 ; control , 64.4 ) including patients from 8 placebo - and active-controlled studies ( including patients with renal impairment or high risk of cardiovascular disease , and older patients ) .